# A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

> **NCT05599334** · — · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 111 (actual)

## Conditions studied

- Breast Cancer
- Adjuvant Therapy
- HER2-positive Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05599334
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05599334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05599334, "A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05599334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*